Fewer patients will be taking the antidepressant Serzone

February 2003

Fewer patients will be taking the antidepressant Serzone...due to concerns about hepatotoxicity.

Bristol-Myers Squibb just pulled it off the market in Europe.

The FDA added a black box warning last year.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

New recommendations for testing C-reactive protein (CRP) will change the way you assess cardiovascular risk
potentially serious interaction between the RA drug Arava (leflunomide) and warfarin
Humira (Hu-MARE-ah, adalimumab), a new biologic therapy for rheumatoid arthritis
Fewer patients will be taking the antidepressant Serzone
There's a potential for errors with Depakote ER and Depakote
whether Serevent is safe
Singulair (montelukast) for treating seasonal allergic rhinitis
more comprehensive therapy for patients with peripheral arterial disease (PAD)
Substance Use Disorder two steroids being sold as dietary supplements
Substance Use Disorder all kinds of tricks to fool drug tests
Ophthalmology Xalatan is now approved for INITIAL treatment of glaucoma
Heart Failure Not enough heart failure patients get a beta-blocker
Infectious Diseases Alinia (nitazoxanide), a new antiprotozoal drug
Infectious Diseases whether the chickenpox vaccine (Varivax) is effective
Natural Medicines Should herbs and other supplements be stopped before surgery
Practice annual chart of new drugs approved in 2002